Clinical trials: Allergic Disease
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Perennial
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.
- Trial name
- NCT01134705
- Testing
- Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
- Where
- 35 sites in United States
- Volunteers
- 474 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Allergic Rhinitis
Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children
Multicenter, randomized, parallel-group, double-blind, double-dummy, comparative clinical trial of the superiority of the fixed-dose combination of desloratadine 0.5 mg/mL and prednisolone 4 mg/mL from Eurofarma Laboratórios SA…
- Trial name
- DESPRED (NCT05214911)
- Testing
- Desloratadine , Prednisolone, Desloratadine
- Where
- Brazil
- Volunteers
- 262 people
- Sponsor
- Eurofarma Laboratorios S.A.
Perennial Allergic Rhinitis, Obstructive Sleep Apnea
The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
This is a Phase 4 randomized, placebo-controlled, parallel-group, single-center, double-blind study to evaluate the effects of mometasone furoate nasal spray (MFNS) in subjects with Sleep-disordered Breathing (SDB) associated…
- Conditions
- Perennial Allergic Rhinitis, Obstructive Sleep Apnea, Sleep Disorder
- Trial name
- NCT00359216
- Testing
- Mometasone furoate nasal spray
- Volunteers
- 30 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
This is an efficacy study of bepotastine besilate nasal spray in seasonal allergic rhinitis.
- Trial name
- NCT01277341
- Testing
- Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day
- Where
- United States
- Volunteers
- 601 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Safety and Efficacy Study of a Eye Drop for Eye Allergy
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.
- Trial name
- NCT00889330
- Testing
- alcaftadine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vistakon Pharmaceuticals
Allergic Rhinitis
A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies
In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine.
- Trial name
- NCT04162795
- Testing
- Loratadine (Claritin, BAY76-2211)
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- Bayer
Rhinitis, Allergic, Seasonal
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH…
- Trial name
- NCT02256553
- Testing
- MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract), Rescue Medication
- Volunteers
- 102 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
This was a multicenter, uncontrolled, open-label, special drug use study to investigate the safety and efficacy of Xolair by collecting data in its clinical setting in patients with severe to most severe seasonal allergic…
- Trial name
- NCT04648930
- Testing
- Xolair
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Perennial
A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis
The purpose of this pilot study is to compare the effects (effectiveness and safety)of an intranasal corticosteroid (fluticasone furoate nasal spray [FFNS]) with a placebo nasal spray for the treatment of irritant (non-allergic)…
- Trial name
- NCT00730756
- Testing
- Fluticasone Furoate Nasal Spray
- Where
- 5 sites in Thailand
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Allergy;Food, Allergy Wheat
Food Challenge With Barley Starch as Active Comparator
Aim of the present study is to verify in a double-blind placebo controlled food challenge (DBPCFC) test that highly purified barley starch ingredient do not cause allergic reaction in subjects most potential to get allergic…
- Trial name
- BALA (NCT03352856)
- Testing
- Barley starch, Maize starch
- Where
- Finland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lyckeby Starch AB
Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)
This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days…
- Trial name
- NCT00794495
- Testing
- Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec)
- Volunteers
- 122 people
- Sponsor
- Organon and Co
Allergic Asthma
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma
This study will evaluate the efficacy of QGE031 compared to omalizumab in patients with allergic asthma. Each treatment's effect in changing the concentration of inhaled allergen that is required to elicit a 15% fall in the…
- Trial name
- NCT01703312
- Testing
- QGE031, omalizumab
- Where
- 7 sites in Canada, Sweden
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Rhinitis
A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device
This is a research study of a vaccine for allergy to Japanese Red Cedar. The vaccine is called CryJ2-DNA-LAMP Plasmid vaccine. This research study will determine how the vaccine is tolerated and how research participants respond…
- Trial name
- NCT02146781
- Testing
- CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Immunomic Therapeutics, Inc.
Seasonal Allergic Rhinitis, SAR
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
The purpose of this study is to assess the safety and efficacy of an investigational nasal aerosol at two doses compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis in children (6-11 years of age).
- Trial name
- NCT01307319
- Testing
- BDP HFA
- Where
- 45 sites in United States
- Volunteers
- 715 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Perennial
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age…
- Trial name
- NCT00116883
- Testing
- GW685698X aqueous nasal spray
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis, Seasonal Allergic Rhinitis
Post Marketing Surveillance for Contac Bien Z in Japan
This is a post-marketing surveillance study on a marketed cetrizine hydrochloride formulation.
- Trial name
- NCT02020902
- Testing
- Cetrizine hydrochloride
- Where
- Japan
- Volunteers
- 1,552 people
- Sponsor
- GlaxoSmithKline
Allergic Reaction
Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome
A 2-part open-label study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as single and repeat doses of DESF in healthy adults with oral allergy syndrome (OAS).
- Trial name
- OASIS (NCT06527937)
- Testing
- DESF, Epinephrine Injection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Aquestive Therapeutics
Allergic Conjunctivitis
A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season
The study was designed to evaluate the pattern of seasonal allergic signs and symptoms consistent with ongoing ocular allergic inflammation during ragweed season.
- Trial name
- NCT00982163
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- ORA, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.